David Silberman's Insider Trades & SAST Disclosures
David Silberman's most recent trade in Oramed Pharmaceuticals, Inc was a trade of 136,500 Common Stock done . Disclosure was reported to the exchange on Jan. 4, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David Silberman.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Oramed Pharmaceuticals, Inc
|
David Silberman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 136,500 | 366,500 (2%) | 0% | - | Common Stock | |
|
Oramed Pharmaceuticals, Inc
|
David Silberman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 24,500 | 230,000 (1%) | 0% | - | Common Stock | |
|
Oramed Pharmaceuticals, Inc
|
David Silberman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2023 | 97,500 | 205,500 (1%) | 0% | - | Common Stock | |
|
Oramed Pharmaceuticals, Inc
|
David Silberman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 39,000 | 108,000 (0%) | 0% | - | Common Stock | |
|
Oramed Pharmaceuticals, Inc
|
David Silberman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 32,000 | 32,000 | - | - | Stock Option (right to buy) | |
|
Oramed Pharmaceuticals, Inc
|
David Silberman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 19,000 | 69,000 (0%) | 0% | - | Common Stock | |
|
Oramed Pharmaceuticals, Inc
|
David Silberman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
|
Oramed Pharmaceuticals, Inc
|
David Silberman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2021 | 50,000 | 50,000 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges